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Depression in oncology patients is under-recognised and associated with poor outcomes. Screening can increase case recognition.
The Brief Case-Find for Depression (BCD) is a four-question, interviewer-administered instrument that has been previously validated
in a general medical setting. The primary aim of this study was to validate the BCD in a medical oncology/palliative care setting,
primarily by comparing its association with physical illness measures and with the Primary Care Evaluation of Mental Disorders
(PRIME-MD), the Beck Depression Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS). Eligible adult oncology
patients gave informed consent and completed the above measures and a pain scale. Agreement between the BCD and other
instruments was assessed. Construct validity was determined by comparing depressed/nondepressed patients with respect to
performance status, symptoms, pain score and functional impairment. A total of 100 patients had a median age of 58 (range 21–90)
and ECOG performance status (PS) 2 (0–4). In all, 60% had metastatic disease. The therapeutic goal was curative/adjuvant in 39%
and palliative in 61%. Prevalence of depression according to the various measures was: BCD 34%, PRIME-MD 12%, BDI 19% and
HADS 14%. In total, 45% of patients responded positively to a single-item screening question. The BCD showed fair agreement with
the PRIME-MD (kappa¼0.21), moderate agreement with the BDI (kappa¼0.43) and fair agreement with the HADS (kappa¼0.27).
Against the PRIME-MD diagnosis of depression, the BCD had greater sensitivity, but lesser specificity and overall agreement,
compared with the BDI and depression scale of the HADS. Patients with probable depression (according to BCD) had inferior PS
(P¼0.0064), increased pain (P¼0.045) and greater impairment of functioning (PRIME-MD: P¼0.0003). There was no association
with gender, age, disease status or therapeutic goal. Depression is common in oncology patients. The BCD is a quick, easy-to-
administer screen for depression, which has reasonable psychometric properties in this population.
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Depression is common in medical oncology and palliative care
patients. The reported incidence of major depression at any point
during the cancer journey varies greatly because of methodological
differences and inconsistencies, though it is often reported to be
around 25% (Bukberg et al, 1984; Lansky et al, 1985; Kathol et al,
1990; Massie and Holland, 1990; Portenoy et al, 1994). Depression
appears to be more common in patients with pain, advanced
illness and higher levels of disability (Bukberg et al, 1984; Lansky
et al, 1985; Katon and Sullivan, 1990; Massie and Holland, 1990;
Massie and Holland, 1992; Spiegel et al, 1994).
There is considerable evidence that physicians and nursing staff
under-recognise depression in oncology patients (Hardman et al,
1989; Ford et al, 1994; Newell et al, 1998; Passik et al, 1998;
McDonald et al, 1999). Underdiagnosis of depression may result in
poor patient outcomes as well as impact upon others, such as
family and friends. Depression may be associated with a reduced
ability to enjoy life and to participate in social interactions, as well
as poor compliance with medical treatment, inferior pain control,
increased hospitalisation and an increased risk of suicide
(Breitbart, 1987; Spiegel, 1996; Block, 2000; DiMatteo et al, 2000).
Treatment for depression in the oncology and palliative care
settings has been shown to be effective. Optimal management
combines supportive psychotherapy, cognitive–behavioural tech-
niques and antidepressant medications (Massie and Holland, 1990;
Spiegel, 1996; Block, 2000; Gill and Hatcher, 2003).
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lDiagnostic criteria for a major depressive episode are defined
within the Diagnostic and Statistical Manual of Mental Disorders
of the American Psychiatric Association (DSM-IV, 1994). The
diagnosis requires a constellation of symptoms, present for at least
2 weeks and representing a change from previous functioning. At
least one of the symptoms must be either depressed mood or loss
of interest or pleasure (anhedonia). Some patients may not satisfy
the DSM-IV diagnostic criteria for a major depressive episode but
may still suffer from significant psychological morbidity. A range
of additional disorders including adjustment disorder with
depressed mood can also be recognised and may benefit from
treatment (Hotopf et al, 2002).
Depression may be distinguished from normal sadness and
anticipatory grief on the basis of the nature and severity of
symptoms, their duration and intensity and their impact upon
functioning. The clinical psychiatric interview is often considered
the gold standard for the diagnosis of depression. However, such
consultations are time-consuming, not always available and may
be inconvenient for patients already requiring multiple hospital or
clinic visits. Therefore, in an effort to improve the recognition of
depression, a number of screening instruments have been
developed. Few such instruments have been studied in the
oncology setting and none have been implemented into routine
clinical care.
The Primary Care Evaluation of Mental Disorders (PRIME-MD)
Patient Health Questionnaire is a validated tool for the diagnosis of
mental disorders. The patient-completed questionnaire is a simple,
though structured way to establish a diagnosis of major depressive
syndrome and panic syndrome, according to DSM-IV symptom
criteria, though excluding the duration criteria (Spitzer et al,
1999). In addition to making a criteria-based diagnosis of a
depressive disorder, the PRIME-MD is also a reliable and valid
measure of depression severity (Kroenke et al, 2001). The Beck
Depression Inventory (BDI) (Beck et al, 1961; Richter et al, 1998)
and the Hospital Anxiety and Depression Scale (HADS) (Zigmond
and Snaith, 1983) are other commonly used, patient-completed
screening instruments. However, there have been concerns
expressed that these instruments may not be ideal screening tools
within the oncology setting (Urch et al, 1998; Love et al, 2002),
with the PRIME-MD appearing to have operating characteristics
superior to HADS (Lowe et al, 2004).
The Brief Case-Find for Depression (BCD – Figure 1) (Clarke
et al, 1994) is a further simple screening tool that has been used
within general medical and geriatric populations to identify
patients with depression. It is a clinician-completed four-
question instrument intended to be administered during the
course of a normal clinical interview. As the clinician completes
the instrument in around 1min, it is particularly suitable
for patients who are frail or exhausted. Component items
were derived from the General Health Questionnaire (GHQ)
(Goldberg, 1972), facilitated by a computer-assisted technique
that sought to find the best items to identify both major
depression and minor depression (adjustment disorders) (Clarke
et al, 1994). The BCD is acceptable to patients and easy to
administer and score. In a validation study, performed in the
setting of a general teaching hospital, the BCD performed better
than the standard GHQ, HADS and BDI (Clarke et al, 1994).
The utility of the BCD in patients with cancer has not been
formally assessed.
The primary aim of this trial, therefore, was to validate the BCD
in a medical oncology and palliative care setting, firstly by
assessing for agreement with factors known to associate with
depression, such as pain and poor performance status, and,
secondly, by comparing the performance of the BCD with the
PRIME-MD and also with the BDI and HADS. A further aim was to
determine the prevalence of ‘cases’ of likely depression (as
determined by the BCD, PRIME-MD, BDI and HADS) in this
patient care setting.
Instructions:The following four questions serve as a ‘screen’ for depression in the medically 
ill. Ask the patient each question exactly as written. If the patient does not understand or asks for 
explanation repeat the question. The words in parentheses may be used for further explanation. 
[A or B] AND [C or D] = probable depression. 
Over the past couple of weeks, have you.... 
 Y   N
 
 ( A) been having restless or disturbed nights?
or 
  (B) been feeling unhappy or depressed?
and 
     (C) felt unable to overcome your difficulties? 
        (‘problems of life that have been worrying you’)
   or 
(D) been dissatisfied with the way you’ve been  
doing things?
        (‘things that you’ve had to do at home or at  
work’)
 Yes  LIKELY DEPRESSION 
 No   UNLIKELY DEPRESSION 
Figure 1 The Brief Case-Find for Depression (BCD).
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lChochinov et al (1997) have suggested that a single-item screen,
essentially asking ‘Are you depressed?’ is an accurate screen for
depression. We therefore also assessed the performance of
question 2 of the BCD (‘Over the past couple of weeks, have you
been feeling unhappy or depressed?’) operating as a single-item
screen.
MATERIALS AND METHOD
Eligibility
To be eligible, patients were required to have a histological or
cytological diagnosis of cancer, be aged 18 or older, be able to
independently complete the English version of the PRIME-MD,
BDI, HADS and McGill Melzack Pain Questionnaire (Walsh and
Bowman, 1982) and were required to provide written informed
consent. Exclusion criteria included dementia or other psychiatric
illness and the presence of a cognitive disorder that might preclude
accurate completion of the patient-completed measures. Patients
considered by their physician to be too debilitated to complete the
study questionnaires were also excluded. The study was approved
by the ethics committee of the Peter MacCallum Cancer Centre.
Study design
A target sample size of 100 eligible patients was chosen for
pragmatic reasons. After each patient had provided informed
consent, the investigating doctor completed the BCD. The patient
then completed, in order, the self-report version of the PRIME-
MD, the BDI and HADS. Patients also completed the Present Pain
Intensity component of the McGill Melzack Pain Questionnaire.
The doctor administering the BCD scored the BCD and the
PRIME-MD immediately after their completion. The patient’s
treating doctor was notified of any patient recognised as being
probably depressed based on either the BCD or the PRIME-MD,
and was responsible for managing the patient in accordance with
treatment recommendations specified within the protocol regard-
ing counselling and the use of antidepressant medications.
Statistical analysis
Quality control Data were entered into a project-specific Micro-
soft Access (Microsoft Corporation, Redmond, WA, USA) database
and were independently verified using a double-data-entry
procedure.
Scoring of the instruments
Brief Case-Find for Depression: Patients were scored as a
probable case of depression if they answered yes to at least one
of questions A and B and to at least one of questions C and D (see
Figure 1).
PRIME-MD: Patients were scored as having a ‘major depressive
syndrome’ on the PRIME-MD if they answered at least ‘more than
half the days’ to questions 1a OR 1b AND to five or more of
questions 1a–i, with the exception that 1i was scored positively if
there was any positive response. Patients were scored as having an
‘other depressive syndrome’ if they answered at least ‘more than
half the days’ to questions 1a OR 1b AND to two, three or four of
questions 1a–i, with the exception that 1i was scored positively if
there was any positive response. Patients were scored as having a
panic syndrome if they answered ‘yes’ to all of questions 2a–e.
Beck Depression Inventory: Each of the 21 questions was scored
on a four-point scale (0–3) and aggregated. Cutoff scores were
those commonly used (Richter et al, 1998), specifically: o10 –
none or minimal depression, 10–18 – mild to moderate
depression, 19–29 – moderate to severe depression and 30–63 –
severe depression.
Hospital Anxiety and Depression Scale: The seven depression
questions were scored on a four-point scale (0–3) and aggregated.
Cutoff scores used were those commonly used (Herrmann, 1997),
specifically: o7 – non-case, 8–10 – doubtful case, X11 – definite
case. The seven anxiety items were scored and aggregated in the
same way.
Comparison of screening tools The PRIME-MD was used as a
surrogate standard for the diagnosis of a major depressive episode,
as this instrument essentially represents a checklist for the DSM-IV
diagnostic criteria for major depressive episode. Kappa values
were calculated to determine the correspondence between the BCD
and PRIME-MD and with BDI and HADS. The strength of
agreement has been interpreted as given by Landis and Koch
(1977). The percentage agreement between the PRIME-MD and
each of the screening tools was also calculated, without correcting
for chance, calculated simply as the percentage of cases with the
same classification on both tools. Similarly, the sensitivity and
specificity of the screening tools were calculated relative to the
PRIME-MD. Sensitivity was calculated as the percentage of cases
on the PRIME-MD that were positive on the screening instruments
and specificity was calculated as the percentage of negative cases
on the PRIME-MD that were negative on the screening instru-
ments. The positive predictive value was calculated as the
percentage of positive cases on the screening instruments that
were cases on the PRIME-MD. The negative predictive value was
calculated as the percentage of negative cases on the screening
instruments that were truly negative on the PRIME-MD.
Pre-specified hypotheses The study tested the following hypoth-
eses, established prospectively and stated in the protocol.
1. Depressed patients, compared to nondepressed patients, as
determined by the BCD, will have:
a. Higher scores on the global self-assessment of the degree of
difficulty in functioning due to problems on the PRIME-MD
b. Poorer ECOG performance status
c. Higher pain scores
d. More advanced/symptomatic disease.
2. There will be at least moderate agreement (kappa40.4)
between:
a. Cases as determined by the BCD and PRIME-MD diagnosis
of major depression
b. BCD and BDI
c. BCD and the HADS depression subscale.
3. There will be only fair agreement (kappa40.2) between:
a. Positive cases on the BCD and positive cases on the panic
scale of the PRIME-MD (patients coded as having a panic
syndrome)
b. Positive cases on the anxiety scale of the HADS.
Methods of analysis Confidence intervals (CIs, 95%) have been
reported for the major summary statistics. For sensitivity and
specificity estimates and other binary outcomes, they have been
based on the Blyth–Still–Casella method (StatXact 5.0.3. CYTEL
Software Corporation, 2001). Comparisons of depressed and
nondepressed patients with respect to binary outcome variables
have been made using Fisher’s exact test. The Cochran–Armitage
test for trend was used for the comparison of ordinal data and the
Wilcoxon–Mann–Whitney test was used for comparison of ages.
One-sided tests of significance were used where positive asso-
ciations were hypothesised in the protocol, otherwise two-sided
tests were used. No adjustment has been made for multiple
comparisons.
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lAll statistical analyses were carried out using StatXact (StatXact
5.0.3. CYTEL Software Corporation, 2001) or SPSS (SPSS for
Windows 11.0.1 SPSS Inc, 2001) statistical software.
RESULTS
Patient characteristics and association with probable
depression on BCD
A total of 102 patients were registered on the trial between October
2001 and December 2002. One patient was found to be ineligible,
being aged 16 at the time of registration, and was thus excluded
from the trial. A second patient was eligible for the trial and was
evaluated with respect to the BCD. However, the patient felt too
unwell to complete the remaining questionnaires and was with-
drawn from the study.
Patient characteristics are given in Table 1. The median age was
58 years (range 21–90). As anticipated, there was a positive
association between depression as identified on the BCD and
ECOG performance status (P¼0.0064) and higher pain scores
(P¼0.045). There was no association with the extent of disease
(none, localised or metastatic) (P¼0.34) or the presence of
symptoms (P¼0.38).
Prevalence of depression in the study population
Overall, 34% of patients were scored as likely cases of depression
on the BCD, compared with 12% on the PRIME-MD, 19% on the
BDI and 14% on the HADS (Table 2). Using less stringent cutoff
scores for caseness, the prevalence of possible depression was
considerably higher on the latter instruments (Table 2).
Association between the BCD and other screening tools
The association between the BCD and other instruments is shown
in Table 3. Agreement with the BCD was fair for the PRIME-MD
(kappa¼0.21), moderate for the BDI (kappa¼0.43) and fair for
the depression subscale of the HADS (kappa¼0.27). There was
only slight agreement between positive cases on the BCD and
positive cases on the anxiety scale of the HADS (kappa¼0.19) and
poor agreement between positive cases on the BCD and positive
cases on the panic scale of the PRIME-MD (kappa¼ 0.02).
Patients with probable depression on BCD had significantly
higher BDI scores and HADS depression scores than patients
without probable depression on BCD (Po0.0001 for all compar-
isons).
As hypothesised, depressed patients according to the BCD,
compared to nondepressed patients, had higher scores on the
PRIME-MD global self-assessment of the degree of difficulty in
functioning due to problems (P¼0.0003).
Association of BCD, BDI and HADS with PRIME-MD
Agreement of the BCD, BDI and HADS with the PRIME-MD is
illustrated in Table 4. Both BDI and HADS had a greater overall
agreement with the PRIME-MD than the BCD. The BCD had
superior sensitivity.
Single item
We examined the responses to question 2 of the BCD, ‘Over the
past couple of weeks, have you been feeling unhappy or
depressed?’ In all, 45% of patients answered ‘yes’ to this question.
However, 24% of cases who were scored as having probable
depression on the BCD answered ‘no’ to this item. Compared with
the BCD as a whole, the single item had lower concordance with
the PRIME-MD – either for ‘major depressive syndrome’ or for
‘other depressive syndrome’.
Table 1 Patient characteristics and association with probable depression
on BCD
Probable
depression on BCD
No Yes Total P-value
Sex
Male 34 (63%) 20 (37%) 54 0.53
a
Female 32 (70%) 14 (30%) 46
Age group
p30 3 (43%) 4 (57%) 7
30–39 5 (50%) 5 (50%) 10
40–49 9 (69%) 4 (31%) 13
50–59 16 (62%) 10 (38%) 26 0.11
b
60–69 22 (76%) 7 (24%) 29
70–79 9 (75%) 3 (25%) 12
X80 1 (50%) 1 (50%) 2
Living arrangements
With others 56 (64%) 31 (36%) 87 0.53
a
Alone 10 (77%) 3 (23%) 13
ECOG performance status
0 15 (94%) 1 (6%) 16
1 26 (67%) 13 (33%) 39
2 16 (57%) 12 (43%) 28 0.0064
c
3 9 (56%) 7 (44%) 16
4 0 (0%) 1 (100%) 1
Type of cancer
Gastrointestinal 18 (78%) 5 (22%) 23
Breast 14 (67%) 7 (33%) 21
Head and neck 7 (70%) 3 (30%) 10
Sarcoma 6 (60%) 4 (40%) 10
Skin 5 (71%) 2 (29%) 7 0.31
d
Gynaecological 3 (50%) 3 (50%) 6
Lung 2 (33%) 4 (67%) 6
Haematological 4 (100%) 0 (0%) 4
Other
e 7 (54%) 6 (46%) 13
Disease status
No evidence of disease 12 (75%) 4 (25%) 16 0.88
d
Localised disease, asymptomatic 2 (50%) 2 (50%) 4
Localised disease, symptomatic 13 (65%) 7 (35%) 20
Metastatic disease, asymptomatic 7 (70%) 3 (30%) 10
Metastatic disease, symptomatic 32 (64%) 18 (36%) 50
No evidence of disease 12 (75%) 4 (25%) 16
Localised disease 15 (63%) 9 (38%) 24 0.34
c
Metastatic disease 39 (65%) 21 (35%) 60
Symptoms
Absent 21 (70%) 9 (30%) 30 0.38
f
Present 45 (64%) 25 (36%) 70
Pain
No pain 27 (77%) 8 (23%) 35
Mild pain 14 (70%) 6 (30%) 20
Discomforting pain 15 (60%) 10 (40%) 25 0.045
c
Distressing pain 6 (40%) 9 (60%) 15
Horrible pain 3 (75%) 1 (25%) 4
Excruciating pain 1 (100%) 0 (0%) 1
Goals of therapy
Curative/adjuvant 26 (67%) 13 (33%) 39 1.00
a
Palliative 40 (66%) 21 (34%) 61
aFisher’s exact test (two-sided).
bWilcoxon–Mann–Whitney test using actual ages
(two-sided).
cCochran–Armitage test for trend (one-sided).
dPearson w
2 test (two-
sided).
eOther cancers were as follows: testicular seminoma, three; metastatic
carcinoma of unknown primary, two; soft tissue neuroendocrine tumour, one; renal
cell carcinoma, one; prostate, one; phaeochromocytoma, one; peripheral neuroecto-
dermal tumour, one; medullary thyroid carcinoma, one; fibrous histiocytoma, one;
carcinoid tumour, one.
fFisher’s exact test (one-sided).
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lDISCUSSION
We aimed to validate the use of the BCD in a medical oncology and
palliative care setting. The BCD is a simple instrument that can be
administered by the treating professional in around 1min as part
of the routine clinical interview, with results available immediately.
We anticipated that, if the BCD demonstrated reasonable
psychometric properties, it could be introduced into standard
clinical practice.
We found fair agreement between the BCD and PRIME-MD,
moderate agreement between positive cases on the BCD and BDI
and fair agreement between the BCD and HADS. This variation in
levels of agreement suggests that the BCD, the HADS and the
PRIME-MD are not measuring exactly the same construct. The
prevalence rate of depression was also different for the different
instruments, suggesting that each may have different thresholds of
severity for caseness. The BCD is a broad screen (with a base rate
of screening positive of 34%) and therefore tends to be over-
inclusive, but has good sensitivity and negative predictive power,
though poorer specificity. As it is a broad screen, it is not
surprising that agreement is greater with the BDI and lesser with
the PRIME-MD (which identifies major depression) and the HADS
(which focuses on anhedonic depression).
As expected, patients with probable depression on BCD had
significantly higher BDI scores, HADS depression scores and
HADS anxiety scores compared with patients without probable
depression. Additionally, depressed patients according to the BCD,
compared to nondepressed patients, had significantly higher
scores on the PRIME-MD global self-assessment of the degree of
difficulty in functioning due to problems. These results suggest
good convergent validity of the BCD.
As anticipated, we found only slight agreement between positive
cases on the BCD and positive cases on the anxiety scale of the
HADS, and poor agreement between cases on the BCD and positive
cases on the panic scale of the PRIME-MD. This indicates some
distinction between depression and anxiety states and provides
support for the discriminant validity of the BCD.
As others have noted, depression was more frequently
diagnosed in patients with increased pain (Massie and Holland,
1990, 1992; Spiegel et al, 1994). We also confirmed the reported
association between probable depression and impaired functional
capacity (Bukberg et al, 1984; Lansky et al, 1985; Katon and
Sullivan, 1990; Portenoy et al, 1994; Weitzner et al, 1997). This was
seen in the association with ECOG performance status and with the
PRIME-MD item ‘degree of difficulty in functioning due to
problems’.
The sensitivity of the BCD was higher than the other
instruments. We anticipate that a positive result on a screening
instrument should prompt a more thorough psychiatric assess-
ment. Due to the superior sensitivity, the prevalence of likely
depression, as measured by the BCD, was higher compared with
the other instruments. Although screening instruments will yield
some false-positive results, it is preferable that a screening
instrument be over-inclusive, rather than miss potential cases. Of
the 100 patients screened, 26 cases of probable depression on the
BCD were not diagnosed as having a major depressive syndrome
according to the PRIME-MD. This might be expected as PRIME-
MD cases approximate the diagnostic criteria for major depres-
sion, whereas the BCD was designed to recognise both major and
minor depression. The BCD did not detect four cases of major
Table 2 Prevalence of depression in the study population
Prevalence
(%)
95%
CI (%)
BCD (likely depression) 34 25–44
PRIME-MD (major depressive syndrome) 12 7–19
PRIME-MD (major or other depression) 21 13–30
BDI (moderate or severe depression – BDI X19) 19 12–28
BDI (mild, moderate or severe – BDI X10) 43 33–53
HADS (definite case, HADS X11) 14 8–22
HADS (doubtful or definite case, HADS X8) 19 12–28
Table 3 Association between BCD and other screening/diagnostic tools
Probable depression
on BCD
N (row percent)
No Yes Total P-value
Major depression on PRIME-MD
No 62 (70%) 26 (30%) 88
Yes 4 (33%) 8 (67%) 12 0.015
a
Other depression on PRIME-MD
No 63 (69%) 28 (31%) 91
Yes 3 (33%) 6 (67%) 9 0.039
a
Major or other depression on PRIME-MD
No 59 (75%) 20 (25%) 79
Yes 7 (33%) 14 (67%) 21 0.0006
a
Degree of difficulty in functioning due to problems identified on PRIME-MD
b
Not difficult at all 39 (83%) 8 (17%) 47
Somewhat difficult 19 (49%) 20 (51%) 39
Very difficult 2 (33%) 4 (67%) 6
Extremely difficult 1 (33%) 2 (67%) 3 0.0003
c
BDI depression score
Mean (s.d.) 7.7 (5.3) 18.1 (9.7) 11.2 (8.6)
Median (range) 6 (0–21) 17.5 (4–40) 8 (0–40) o0.0001
d
BDI depression group
None or minimal 49 (86%) 8 (14%) 57
Mild 13 (54%) 11 (46%) 24
Moderate 4 (27%) 11 (73%) 15
Severe 0 (0%) 4 (100%) 4 o0.0001
c
HADS depression score
Mean (s.d.) 3.2 (3.2) 7.4 (4.6) 4.6 (4.2)
Median (range) 2 (0–14) 6 (2–19) 3 (0–19) o0.0001
d
HADS depression group
Non-case 60 (74%) 21 (26%) 81
Doubtful case 2 (40%) 3 (60%) 5
Definite case 4 (29%) 10 (71%) 14 0.0006
c
aFisher’s exact test (one-sided).
bExcludes three patients who did not record any
problems on PRIME-MD and two patients who recorded problems but did not
answer question 3.
cWilcoxon–Mann–Whitney test (one-sided).
dCochran–
Armitage test for trend (one-sided).
Table 4 Comparison of screening tools with the PRIME-MD major
depression
BDI HADS
BCD (score X19) (score X11)
Base rate of screening positive 34% 19% 14%
Kappa 0.34 0.44 0.49
% agreement 73% 82% 85%
Sensitivity 67% 52% 48%
Specificity 75% 90% 95%
Positive predictive value 41% 58% 71%
Negative predictive value 89% 88% 87%
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ldepressive syndrome identified on the PRIME-MD. It is uncertain
whether these cases represent true false negatives. Certainly all
patients with probable depression should be followed with an
appropriate diagnostic interview.
Concerning the effectiveness of a single-item screen, the study
by Chochinov et al (1997) has been critiqued by Swanwick and
Wrigley (1998), who have suggested that many older patients may
fail to complain of low mood. A recent study by Lloyd-Williams
et al (2003) also found that a similar single item had relatively low
sensitivity (55%) and specificity (74%) when compared to a
semistructured clinical psychiatric interview. It is possible that
some depressed people acknowledge anhedonia but do not
acknowledge feeling depressed. In this study, around a quarter
of all cases answered ‘no’ to the relevant single item. This is clearly
a limitation of a single-item screen.
In this study, we did not assess the impact of case finding on the
subsequent management of patients. The importance of detecting
possible cases of depression is that this should prompt further
assessment and, if necessary, management of cases of likely
depression. Our study aimed, primarily, to determine the validity
of the BCD. We are now investigating the feasibility of routine
implementation of the BCD, initially for hospitalised patients. Our
approach incorporates education and training for resident medical
officers regarding depression in general, administration of the
BCD, responding appropriately to emotional cues/distress and
facilitation of referral to psycho-oncology services. The imple-
mentation pilot will assess the impact of the routine administra-
tion of the BCD on staff practice/satisfaction/workload (resident
medical staff, psycho-oncology and ward staff) and on patient
outcomes (referrals, final psychiatric diagnosis, treatments and
response to treatments).
CONCLUSIONS
Depression is common in a medical oncology and palliative care
setting. We found that the BCD is a simple screen, which is easy to
administer and has good psychometric properties – good
sensitivity and negative predictive power. We confirmed pre-
viously noted associations between depression and both increased
pain and impaired functional capacity. The BCD also showed
concordance with other depression screening tools. The BCD
proved simple for patients and professionals to use. Further work
will aim at studying the impact of routine implementation of the
BCD and will assess the impact of the BCD upon physician
practices and upon patient outcomes.
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